Wanbury Ltd Stock Analysis

BSE: 524212 | NSE: WANBURY | Pharmaceuticals & Drugs | Small Cap

BSE Share Price 29-Sep-2023 16:00
69.80 1.36 (1.99%)

DeciZen - Make an Informed Decision on Wanbury

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity

1. Quality

2. Valuation

Somewhat overvalued

3. Price Trend

Wanbury Price Chart

P/E Ratio (SA):
Market Cap:
224 Cr.
52-wk low:
52-wk high:
Bole Toh?

1. Is Wanbury Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Wanbury Ltd is a average quality company.

2. Is Wanbury Ltd undervalued or overvalued?

The key valuation ratios of Wanbury Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

3. Is Wanbury Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Wanbury Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

10 Year X-Ray of Wanbury:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Wanbury Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

ROCE % -0.9%-17%5.5%7.4%46.9%-11.1%6%61.3%11.2%101.5%-
Value Creation Index -1.1NANANA2.4NANA3.4NA6.3-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 414441500423434371391367393511529
YoY Gr. Rt. %-6.5%13.3%-15.3%2.5%-14.5%5.5%-6.1%6.8%30.2%-
Adj EPS -15.2-32.6-1.1-3.324.9-13.9-10.42.5-4.8110.5
YoY Gr. Rt. %-NANANANA-155.7%NANA-293.9%NA-
BVPS (₹) 39.9-64.1-193-99.3-54.9-67.2-77.5-47.2-52.40.3-1.4
Adj Net Profit -26.5-65.2-2.2-6.657.8-32.9-24.66.2-11.935.82
Cash Flow from Ops.
Debt/CF from Ops.


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 2.4%3.3%9.3%30.2%
Adj EPS NA-15.1%NANA
Share Price 11.9% 27.5% 27.3% 7.4%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity % -20.8376.50.74-39.82314.4-4.19.6-55.7-81.7
Op. Profit Mgn %
Net Profit Mgn % -6.4-14.8-0.4-1.613.3-8.9-6.31.7-370.3
Debt to Equity 6-2-2-1.9-2.1-1.4-1.3-1.4-1.271.5-
Working Cap Days 282147295162159127748678840
Cash Conv. Cycle 4621152-17-51-59-81-77-650

Recent Performance Summary

No data to display

Return on Equity is Poor

Sales growth has been subdued in last 3 years 9.31%

Net Profit has been subdued in last 3 years 0.00%

Debt to equity has increased versus last 3 years average to 71.51

Sales growth is not so good in last 4 quarters at 6.17%

Latest Financials - Wanbury Ltd.

Standalone Consolidated
TTM EPS (₹) 0.5 0.5
TTM Sales (₹ Cr.) 529 529
BVPS (₹.) -1.4 -9.3
Reserves (₹ Cr.) -37 -63
P/BV -47.66 -7.39
PE 145.77 145.86
From the Market
52 Week Low / High (₹) 33.05 / 70.90
All Time Low / High (₹) 0.85 / 267.00
Market Cap (₹ Cr.) 224
Equity (₹ Cr.) 32.7
Face Value (₹) 10
Industry PE 41.7

Management X-Ray of Wanbury :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *76.7676.7676.7676.7676.7676.7476.740.0076.7476.74
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Wanbury

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)


Wanbury Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Wanbury on 29-Sep-2023 16:00 is : 69.80.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 29-Sep-2023 16:00 the market cap of Wanbury stood at ₹ 224.0.
The latest PE ratio of Wanbury as of 29-Sep-2023 16:00 is 145.8.
The latest PB ratio of Wanbury as of 29-Sep-2023 16:00 is -47.66
The 52-week high of Wanbury is ₹ 70.90 and the 52-week low is ₹ 33.05.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Wanbury is ₹ 529.0 ( Cr.) .

About Wanbury Ltd

Wanbury was incorporated in 1990 as a private limited company under the name of Pearl Distributors Private Limited. The name of the company was changed to 'Pearl Organics Private Limited on January 17, 1991 and the company was converted into a public limited company on August 6, 1991.

Wanbury is the fastest growing pharma company amongst top 100 companies in India as per ORG-IMS has strong presence in domestic branded formulations. Wanbury’s major thrust area also lies in Active Pharmaceutical Ingredient (API) and Contract Research and Manufacturing Services (CRAMS). It has a presence in Spain through its branded formulation business - Cantabria Pharma S. L acquired in 2006.

The company is having 3 API manufacturing facilities including 2 US FDA approved multi-product API facilities for regulated markets.

Product range of the company includes:

  • Coriminic table
  • Cpink table
  • Nock 2 tab
  • Senasof tab
  • Zevanuron
  • Rabiplus cap
  • Folinine
  • Cpink-s
  • Nuture
  • Adtrol 200mg


2008Wanbury opened an office in Zurich, Switzerland for its CRAMS business. Wanbury incorporated Wanbury Global FZE in Middle East for expanding its global business.Wanbury achieved consolidated turnover of Rs. 630 crore for 18 months period ended 30th September 2008. Rabiplus was awarded ‘Best Brand Launch’ by ORG-IMS as it did sales of Rs.13.8 crores in launch Year. Wanbury is the fastest growing company among top 100 companies in India as per ORG-IMS.

2007Doctor’s Organics Chemicals merged with Wanbury. Wanbury entered into a strategic association with Bravo Healthcare Wanbury incorporated Ningxia Wanbury Fine Chemicals Co to source raw materials from China. Wanbury approved as preferred Vendor by Pfizer (US) for Contract Research and Manufacturing Services (CRAMS). Cpink was awarded ‘Best Brand Launch’ by ORG-IMS as it did sales of Rs. 11 crores in launch year. Wanbury is the fastest growing company among top 100 companies in India as per ORG-IMS.

2006Wanbury achieved 100 crore turnover. Pharmaceutical Products of India (PPIL) merged with Wanbury pursuant to BIFR order. Wanbury acquired Cantabria Pharma S.L. with presence in ethical branded formulations in the Spanish market. Wanbury crossed 1000 employees mark. Wanbury became the world’s largest producer of Metformin with production of 4500 MT.

2005Wanbury acquired Doctor’s Organics and Chemicals, having a US FDA approved facility for manufacturing multi-product API’s.

2004Wander merged with Pearl Organics Limited and Pearl Organics renamed as Wanbury Wanbury set up its R & D center in Navi Mumbai for API. Wanbury started using SAP as a business transaction system.

2002Pearl Organics got US FDA approval for Patalganga plant.

1996Pearl Organics entered into a strategic alliance with Wyckoff Chemicals (US) to market its API in US.

1995Pearl Organics acquired plant of Brij Chemicals Pvt at Patalganga (Maharashtra).

1992Pearl Organics established its first plant in Tarapur for manufacturing API’s.

1991Pearl Distributors Pvt went public and was renamed as Pearl Organics.

1990Incorporated as Pearl Distributors Pvt

Achievements/ recognition:-

  • Wanbury ranks 47th as per ORG-IMS (Jan-2009) 
  • Cpink awarded “Best Brand Launch' by ORG IMS (06-07)  
  • Rabiplus awarded “Best Brand Launch' by ORG IMS (07-08) 
  • World's largest producer of Metformin
  • Fastest growing company amongst top 100 companies in the domestic market as per ORG IMS.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now